Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 20-519
Application: Useful for binding assays.
Assay Conditions: A 96-well plate was coated with IL-31, His-Avi-Tag Recombinant (100 ng/well in PBS) at 4°C overnight. The plate was washed three times with PBST, and 200 µl of Blocking Buffer 2 was added for 2 hours at Room Temperature (RT). After three washes with PBST, a 1:2 serial dilution of IL-31Ra protein prepared in PP-02 Assay Buffer (BPS Bioscience #82620), was added and the plate was incubated at RT for 1 hour. The plate was washed three times and incubated with Anti-human Fc-HRP conjugate diluted 1:1000 in Blocking Buffer 2 for 1 hour at RT. After three washes, 100 µl of the ELISA ECL Substrate (BPS Bioscience #79670) was added to each well and chemiluminescence was measured.
Background: IL-31 (interleukin 31) is a four-helix bundle proinflammatory cytokine preferentially produced by T helper type 2 (TH2) cells. IL-31 regulates cell differentiation, cell proliferation, and immune responses, serving as a neuroimmune link between TH2 cells and sensory neurons in generating a T cell-mediated inflammatory itch. The IL-31 receptor complex, composed of IL-31RA and OSMR (human oncostatin M receptor beta), is expressed by various epithelial and immune cells as well as dorsal root ganglia sensory neurons. IL-31 interacts with the IL-31 receptor complex, activating Janus kinases JAK1 and JAK2. This activation leads to the phosphorylation of signal transducer and activator of transcription (STAT) molecules, mainly STAT3, which upregulate the genes responsible for the IL-31 induced itch sensation. Often referred to as the itchy cytokine, increased expression of IL-31 or its receptor IL-31RA is correlated with alopecia, skin lesions, airway hypersensitivity, and particularly pruritic disorders such as atopic dermatitis. IL-31 and other TH2 related cytokines (including IL-4, IL-13 and TSLP (thymic stromal lymphopoietin) play an important role in the pathogenesis of a variety of inflammatory and allergic diseases and have become popular for therapeutic development. The IL-31RA targeting antibody Nemolizumab has been FDA-approved for the treatment of atopic dermatitis.
Description: Recombinant human IL-31Ra (Interleukin 31 receptor subunit alpha), encompassing amino acids 20-519, containing the extracellular portion of the receptor. This construct contains at the C-terminus the Fc domain of a human IgG1, followed by an Avi-Tag™. This protein was affinity purified.
Format: Aqueous buffer solution
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol.
Genbank: Q8NI17-1
Host Cell Line: HEK293
Purity: ≥85%
Storage Stability: >6 months at –80°C.
Tags: Fc-Avi
Target: IL-31Ra
Uniprot: Q8NI17
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
